In addition to symptomatic therapies—to manage disease-related symptoms such as heart failure, neuropathic pain, and autonomic dysfunction—there are a growing number of disease-modifying therapy options for ATTR-CM and ATTR-PN [35]. The gene discussed is TTR; the disease is Abnormal autonomic nervous system physiology.